All articles tagged with #finasteride
Medicines often find new uses after their initial purpose; sildenafil, finasteride, and minoxidil were repurposed from heart, prostate, and blood-pressure indications to treat erectile dysfunction and hair loss, illustrating how serendipity and careful observation drive medical progress and highlighting the benefits and caveats of drug repurposing in men's health.
A We Are Austin feature explains how advancements in hair restoration span non-surgical options like finasteride, minoxidil, PRP therapy, and laser treatments to surgical hair transplantation using donor hair. Experts emphasize starting intervention early to slow loss and preserve hair, while discussing patient selection, the importance of follow-up, and the availability of both scalp and body donor hair for density improvements.
The latest White House medical report omits finasteride, a hair-loss drug previously reported to be used by Trump during his first term. White House officials did not explain the omission, prompting questions about health disclosure and transparency, with experts calling for independent assessment of Trump’s health information.
A retrospective TriNetX study of 24,424 androgenetic alopecia patients on finasteride or dutasteride found no increased risk of composite cardiovascular disease or most individual events over 1–5 years; atrial fibrillation risk was lower at 5 years, with other outcomes not significantly different after correction. Limitations include potential confounding and uncertain adherence, but results support CV safety of these drugs in appropriately selected patients.
A long-used hair-loss and prostate drug, finasteride, may lower cholesterol and reduce heart-disease risk, per observational human data and mice experiments. While findings are intriguing, the high-dose mouse results may not translate to humans, and potential side effects exist; further clinical trials are needed to confirm heart-health benefits and safe usage.
A hair-loss guide highlighting minoxidil’s role and five top men’s products: Ulo Minoxidil + Tretinoin Plus (7% minoxidil), Men’s Rogaine 5% Minoxidil Foam, Happy Head Oral Minoxidil, RootStim 5% Minoxidil Spray, and hims Topical Finasteride & Minoxidil Spray. The piece notes 5% minoxidil as the FDA-approved starting dose, with options for higher concentrations; results typically appear after 2–6 months, and potential side effects include scalp irritation, temporary shedding, and, for oral minoxidil, cardiovascular risks. It also covers differences between topical and oral forms and encourages consults with a dermatologist for personalized guidance.
The Healthline piece surveys current and prospective hair‑loss treatments, highlighting established options finasteride and minoxidil as effective, affordable therapies, noting three FDA‑approved JAK inhibitors (Olumiant, Litfulo, Leqselvi) for alopecia areata with safety warnings, and surveying emerging approaches such as clascoterone, PP405, ET-02, stem-cell therapies, and fatty‑acid treatments. While these newer options show promise, many are still in early trials, and long‑term durability and safety remain uncertain. Experts emphasize early intervention and consulting ABHRS‑certified physicians for accurate diagnosis and personalized treatment planning.
A review reveals that the hair-loss drug finasteride has been linked to depression and suicide for over 20 years, but regulators and manufacturers failed to act on the warning signs, highlighting systemic issues in drug safety monitoring and the need for urgent reform.
A recent study highlights a significant link between the hair loss drug finasteride and increased risks of mood disorders and suicidal thoughts, criticizing regulatory and manufacturer oversight for underreporting and neglecting these dangers over the past two decades.
Finasteride, a popular hair loss medication among young men, may cause fertility issues, as illustrated by a case where a man's sperm count was significantly below the normal threshold, potentially impacting conception efforts.
The article discusses how the hair loss medication finasteride, popular among young men, may cause fertility issues, including low sperm count, as illustrated by a case where a man experienced significantly reduced sperm levels after taking the drug.
Dr. Gary Linkov, a New York City plastic surgeon, recommends finasteride as a primary treatment for male pattern hair loss, a drug reportedly used by Donald Trump. Originally for enlarged prostate treatment, finasteride prevents testosterone from converting into DHT, a compound causing hair loss. While effective in slowing hair loss, it may have side effects like decreased libido. Dr. Linkov also prescribes minoxidil to thicken hair. Despite its benefits, finasteride cannot restore lost hair but can delay further loss, especially in young adults.
Finasteride, a drug known for treating hair loss and enlarged prostate, may also lower cholesterol and reduce heart disease risk, according to recent research. Observational data showed men taking finasteride had lower cholesterol levels, prompting further studies in mice, which confirmed the drug's potential to reduce cholesterol and inflammation. This discovery could benefit not only men but also transgender individuals, who face higher cardiovascular risks. However, finasteride's side effects, including sexual and psychological issues, must be considered, and more human trials are needed to confirm these findings.
Millions of Americans using the hair loss drug finasteride report severe and potentially permanent sexual side effects, including erectile dysfunction, low libido, and genital pain. Despite its effectiveness in combating hair loss, the drug has been linked to significant adverse effects on sexual health, with some patients experiencing symptoms even after discontinuation. Calls for FDA warnings or removal of the drug from the market have been made, but scientific evidence remains mixed, necessitating further research.
A study suggests that the hair loss drug finasteride, also used for enlarged prostates, may lower the risk of heart disease by reducing cholesterol levels. Analysis of data from male humans and mice showed potential health benefits and cholesterol reduction with finasteride use. While the study's sample size is small, the findings are promising, prompting the need for further research in diverse groups or clinical trials. The drug's existing approval could expedite this process, potentially benefiting both cisgender and transgender individuals at risk of cardiovascular diseases.